心脏毒性会干扰曲妥珠单抗治疗乳腺癌患者

该研究纳入608例接受曲妥珠单抗治疗的HER2阳性乳腺癌患者，并对因应用曲妥珠单抗出现心脏毒性（TIC）所致治疗干扰的发生率、风险因素和处理进行了评估。研究发现，18%的患者的曲妥珠单抗治疗受到干扰：与未受干扰者相比，药物剂量下调。TIC是治疗受干扰的最常见因素。

曲妥珠单抗治疗受到干扰较为常见，常是因TIC受到干扰。作者强调，应研究减少心脏毒性及其对治疗的干扰的方法。

独家授权，未经许可，请勿转载

The incidence, risk factors, and management of trastuzumab interruption due to treatment-induced cardiotoxicity (TIC) were assessed in 608 patients with HER2-positive breast cancer receiving trastuzumab. Trastuzumab was interrupted in 18% of patients and was administered at a lower dose compared with dose in patients whose therapy was uninterrupted. TIC was the most common reason for interruption.

Trastuzumab interruption is common and often a result of TIC. The authors stress that methods to minimize cardiotoxicity and treatment interruption should be investigated.

Breast Cancer Research and Treatment

Trastuzumab Interruption and Treatment-Induced Cardiotoxicity in Early HER2-Positive Breast Cancer

Breast Cancer Res Treat 2015 Jan 01;[EPub Ahead of Print], AF Yu, NU Yadav, BY Lung, AA Eaton, HT Thaler, CA Hudis, CT Dang, RM Steingart

---------------------------------------------------------------------------------------------------------------------------------------------
欢迎关注Elseviermed官方微信